Session: S18-Lipids & Cardiometabolic Risk: Hot Topics
Room 307 (Moscone Center)
The benefit of LDL cholesterol lowering with statins is well established. Evidence for the benefit of lowering triglycerides and raising HDL cholesterol is less robust. Recent clinical outcomes trials have failed to provide conclusive evidence for a significant effect on cardiovascular outcomes of various pharmacologic approaches to raising HDL cholesterol. The heterogeneity of disorders of triglyceride and HDL metabolism makes designing trials difficult. This talk will discuss some of the evidence from recent clinical trials and some of issues surrounding treatment decisions.